<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Research Results in Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2313-8955-2016-2-3-23-27</article-id><article-id pub-id-type="publisher-id">769</article-id><article-categories><subj-group subj-group-type="heading"><subject>Archive categories</subject></subj-group></article-categories><title-group><article-title>FEASIBILITY STUDIES OF THE DESIGN OF PHARMACEUTICAL DEVELOPMENT AND INDUSTRIAL INTRODUCTION OF PARENTERAL PREPARATIONS ON THE BASIS OF RECOMBINANT PROTEINS</article-title><trans-title-group xml:lang="en"><trans-title>FEASIBILITY STUDIES OF THE DESIGN OF PHARMACEUTICAL DEVELOPMENT AND INDUSTRIAL INTRODUCTION OF PARENTERAL PREPARATIONS ON THE BASIS OF RECOMBINANT PROTEINS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Goy</surname><given-names>Andrey M.</given-names></name><name xml:lang="en"><surname>Goy</surname><given-names>Andrey M.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Voskoboynikova</surname><given-names>Galina L.</given-names></name><name xml:lang="en"><surname>Voskoboynikova</surname><given-names>Galina L.</given-names></name></name-alternatives><email>G_Vosk@ukr.net</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Gapon</surname><given-names>Natalia V.</given-names></name><name xml:lang="en"><surname>Gapon</surname><given-names>Natalia V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Kuznets</surname><given-names>Dmitro O.</given-names></name><name xml:lang="en"><surname>Kuznets</surname><given-names>Dmitro O.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2016</year></pub-date><volume>2</volume><issue>3</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2016/3/23-27.pdf" /><abstract xml:lang="ru"><p>In the conditions of introduction of the proper practice of production of medicinal facilities on pharmaceutical enterprises in Ukraine, it is necessary to develop effective measures of projects management for creation of favourable conditions for modernisation of pharmaceutical production, innovative management and management of development projects. The optimization of pharmaceutical production of injection preparations, modernisation of the pharmaceutical industries, is being implemented in accordance with the standards of GMP. Risks-control of pharmaceutical production of hi-tech parenteral preparations on a new level is carried out at the following stages: preparation of raw material, preparation of facilities and equipment; the process of preparation of solution (the stage of preparation of solution, the stage of sterile filtration; filling, small bottles, ampoules and cartridges; washing small bottles, ampoules and cartridges, preparation of materials for corking, sterilization of components; soldering of ampoules, rolling of small bottles and cartridges; sterilization and checking for impermeability). Decreasing the risk focuses on the processes of reduction and prevention of risk and its causes, when the risk exceeds the indicated acceptable level. Decreasing the risk can include the measures of declining of authenticity of harm. Conclusions regarding the measures related to decreasing the risk can bring to the exposure of potential threats and new hidden risks.</p></abstract><trans-abstract xml:lang="en"><p>In the conditions of introduction of the proper practice of production of medicinal facilities on pharmaceutical enterprises in Ukraine, it is necessary to develop effective measures of projects management for creation of favourable conditions for modernisation of pharmaceutical production, innovative management and management of development projects. The optimization of pharmaceutical production of injection preparations, modernisation of the pharmaceutical industries, is being implemented in accordance with the standards of GMP. Risks-control of pharmaceutical production of hi-tech parenteral preparations on a new level is carried out at the following stages: preparation of raw material, preparation of facilities and equipment; the process of preparation of solution (the stage of preparation of solution, the stage of sterile filtration; filling, small bottles, ampoules and cartridges; washing small bottles, ampoules and cartridges, preparation of materials for corking, sterilization of components; soldering of ampoules, rolling of small bottles and cartridges; sterilization and checking for impermeability). Decreasing the risk focuses on the processes of reduction and prevention of risk and its causes, when the risk exceeds the indicated acceptable level. Decreasing the risk can include the measures of declining of authenticity of harm. Conclusions regarding the measures related to decreasing the risk can bring to the exposure of potential threats and new hidden risks.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>pharmaceutical production</kwd><kwd>injection preparations</kwd><kwd>innovative management</kwd><kwd>management of development projects</kwd><kwd>good manufacturing practice</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pharmaceutical production</kwd><kwd>injection preparations</kwd><kwd>innovative management</kwd><kwd>management of development projects</kwd><kwd>good manufacturing practice</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Refferences</mixed-citation></ref><ref id="B2"><mixed-citation>A Review on parenteral production technology / B. Venkateswara Reddy, B. Rasmitha Reddy, K. Navaneetha, V.Sampath Kumar // International Journal of Pharmacy and Biological Sciences ( IJPBS). &amp;nbsp;2013. Volume 3. Issue 1. P.596-610.</mixed-citation></ref><ref id="B3"><mixed-citation>Lippincott K. Williams. Remington, the Science &amp;amp; practice of pharmacy, Parenteral Preparation, 20th ed., volume‐I, Philadelphia: ISE publication; 2000. &amp;nbsp;804 p.</mixed-citation></ref><ref id="B4"><mixed-citation>Bliem R, Nowak W.G. Inaktivierung von Mikroorganismen durch Sterilisation, Desinfektion oder Pasteurisierung. Pharm Ind. 2004. 66. Pp. 470&amp;ndash;477.</mixed-citation></ref><ref id="B5"><mixed-citation>Bliem R.F., Nowak G.W. Assessment of the Inaccuracy Inherent in the Exponential Model of Sterilization. Pharm Ind. 2004. 66. Pp. 780&amp;ndash;785.</mixed-citation></ref><ref id="B6"><mixed-citation>Decision trees for the selection of sterilization methods URL: (CPMP/ QWP/054/98http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide line /2009/09/WC500003520.pdf (date of access: 20.05.2016).</mixed-citation></ref><ref id="B7"><mixed-citation>Thomas von Woedtke,&amp;nbsp; Axel Kramer. The limits of sterility assurance. Die Grenzen der Sterilisationssicherheit.// GMS Krankenhhyg Interdiszip. 2008. 3(3). &amp;nbsp;Doc19. Published online 2008 Sep 3.</mixed-citation></ref><ref id="B8"><mixed-citation>ISO 13408-1:1998 Aseptic processing of health care products &amp;ndash; Part 1: General requirements.</mixed-citation></ref><ref id="B9"><mixed-citation>Risk-MaPP: Manging the risk of cross contamination. Stephanie Wilkins at PharmaConsult US, Innovations in Pharmaceutical Techonology, EMA Statement on status of revision of Chapter 5 of the GMP guide concerning &amp;quot;dedicated facilities&amp;quot;, London. 9 January 2008. Doc. Ref. EMEA/INS/GMP/14529/2008 (date of access: 20.05.2016)</mixed-citation></ref><ref id="B10"><mixed-citation>FDA and Pharmaceutical Manufacturing Research Projects / Jeffrey T. Macher, Jackson A. Nickerson and all. URL: http://apps.olin.wustl.edu/faculty/nickerson/results (date of access: 20.05.2016).</mixed-citation></ref><ref id="B11"><mixed-citation>WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-seventh Report. Geneva, World Health Organization, 2003. (WHO Technical Report Series № 908).&amp;nbsp; Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals.&amp;nbsp; P. 99 &amp;ndash; 112.</mixed-citation></ref></ref-list></back></article>